Which has stronger valuation and earnings, SVRA or ACIU?

AC Immune has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A AC Immune $4.31M 62.57 -$85.03M -$0.54 N/A

Is SVRA or ACIU more profitable?

Savara has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Savara's return on equity of -90.28% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% AC Immune -245.32% -100.17% -28.36%

Does the media prefer SVRA or ACIU?

In the previous week, Savara had 8 more articles in the media than AC Immune. MarketBeat recorded 10 mentions for Savara and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.28 beat Savara's score of 1.27 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AC Immune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACIU or JANX?

In the previous week, Janux Therapeutics had 7 more articles in the media than AC Immune. MarketBeat recorded 9 mentions for Janux Therapeutics and 2 mentions for AC Immune. Janux Therapeutics' average media sentiment score of 1.38 beat AC Immune's score of 1.28 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ACIU or IMMX more profitable?

Immix Biopharma has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Immix Biopharma's return on equity of -38.44% beat AC Immune's return on equity. Company Net Margins Return on Equity Return on Assets AC Immune -245.32% -100.17% -28.36% Immix Biopharma N/A -38.44% -34.72%

Does the media prefer ACIU or IMMX?

In the previous week, Immix Biopharma had 3 more articles in the media than AC Immune. MarketBeat recorded 5 mentions for Immix Biopharma and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.28 beat Immix Biopharma's score of 1.16 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immix Biopharma 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACIU or AVTX?

In the previous week, AC Immune and AC Immune both had 2 articles in the media. AC Immune's average media sentiment score of 1.28 beat Avalo Therapeutics' score of 0.94 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ACIU or SLDB?

In the previous week, Solid Biosciences had 3 more articles in the media than AC Immune. MarketBeat recorded 5 mentions for Solid Biosciences and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.28 beat Solid Biosciences' score of 0.92 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

AC Immune (ACIU) Competitors

$2.65 -0.06 (-2.21%)

As of 08/28/2026 04:00 PM Eastern

Compare

ACIU vs. SVRA, JANX, IMMX, AVTX, and SLDB

Should you buy AC Immune stock or one of its competitors? AC Immune's main competitors and comparable companies include Savara (SVRA), Janux Therapeutics (JANX), Immix Biopharma (IMMX), Avalo Therapeutics (AVTX), and Solid Biosciences (SLDB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does AC Immune compare to Savara?

Savara (NASDAQ:SVRA) and AC Immune (NASDAQ:ACIU) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

AC Immune has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
AC Immune	$4.31M	62.57	-$85.03M	-$0.54	N/A

In the previous week, Savara had 8 more articles in the media than AC Immune. MarketBeat recorded 10 mentions for Savara and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.28 beat Savara's score of 1.27 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AC Immune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

Savara has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Savara's return on equity of -90.28% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
AC Immune	-245.32%	-100.17%	-28.36%

87.9% of Savara shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Savara currently has a consensus target price of $10.14, suggesting a potential upside of 92.83%. AC Immune has a consensus target price of $7.50, suggesting a potential upside of 183.02%. Given AC Immune's higher possible upside, analysts plainly believe AC Immune is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Savara and AC Immune tied by winning 8 of the 16 factors compared between the two stocks.

How does AC Immune compare to Janux Therapeutics?

AC Immune (NASDAQ:ACIU) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

AC Immune currently has a consensus target price of $7.50, indicating a potential upside of 183.02%. Janux Therapeutics has a consensus target price of $36.46, indicating a potential upside of 102.23%. Given AC Immune's higher probable upside, research analysts clearly believe AC Immune is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

AC Immune has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

AC Immune has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	62.57	-$85.03M	-$0.54	N/A
Janux Therapeutics	$10M	110.24	-$113.62M	-$1.64	N/A

In the previous week, Janux Therapeutics had 7 more articles in the media than AC Immune. MarketBeat recorded 9 mentions for Janux Therapeutics and 2 mentions for AC Immune. Janux Therapeutics' average media sentiment score of 1.38 beat AC Immune's score of 1.28 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Janux Therapeutics' return on equity of -11.89% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Janux Therapeutics	N/A	-11.89%	-11.13%

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 4.6% of AC Immune shares are owned by company insiders. Comparatively, 7.9% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Janux Therapeutics beats AC Immune on 13 of the 17 factors compared between the two stocks.

How does AC Immune compare to Immix Biopharma?

AC Immune (NASDAQ:ACIU) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Immix Biopharma has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Immix Biopharma's return on equity of -38.44% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Immix Biopharma	N/A	-38.44%	-34.72%

Immix Biopharma has lower revenue, but higher earnings than AC Immune. Immix Biopharma is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	62.57	-$85.03M	-$0.54	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

51.4% of AC Immune shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Comparatively, 30.3% of Immix Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

AC Immune presently has a consensus target price of $7.50, suggesting a potential upside of 183.02%. Immix Biopharma has a consensus target price of $21.29, suggesting a potential upside of 52.70%. Given AC Immune's higher probable upside, equities analysts clearly believe AC Immune is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

AC Immune has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.11, suggesting that its share price is 89% less volatile than the broader market.

In the previous week, Immix Biopharma had 3 more articles in the media than AC Immune. MarketBeat recorded 5 mentions for Immix Biopharma and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.28 beat Immix Biopharma's score of 1.16 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immix Biopharma	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AC Immune beats Immix Biopharma on 8 of the 15 factors compared between the two stocks.

How does AC Immune compare to Avalo Therapeutics?

AC Immune (NASDAQ:ACIU) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

AC Immune has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Avalo Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

Avalo Therapeutics has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Avalo Therapeutics' return on equity of -58.03% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Avalo Therapeutics	N/A	-58.03%	-48.22%

AC Immune currently has a consensus target price of $7.50, indicating a potential upside of 183.02%. Avalo Therapeutics has a consensus target price of $45.10, indicating a potential upside of 130.22%. Given AC Immune's higher possible upside, equities research analysts plainly believe AC Immune is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

51.4% of AC Immune shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 4.6% of AC Immune shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, AC Immune and AC Immune both had 2 articles in the media. AC Immune's average media sentiment score of 1.28 beat Avalo Therapeutics' score of 0.94 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Avalo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Avalo Therapeutics has lower revenue, but higher earnings than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	62.57	-$85.03M	-$0.54	N/A
Avalo Therapeutics	$60K	17,510.20	-$78.26M	-$4.37	N/A

Summary

Avalo Therapeutics beats AC Immune on 8 of the 15 factors compared between the two stocks.

How does AC Immune compare to Solid Biosciences?

AC Immune (NASDAQ:ACIU) and Solid Biosciences (NASDAQ:SLDB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

In the previous week, Solid Biosciences had 3 more articles in the media than AC Immune. MarketBeat recorded 5 mentions for Solid Biosciences and 2 mentions for AC Immune. AC Immune's average media sentiment score of 1.28 beat Solid Biosciences' score of 0.92 indicating that AC Immune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AC Immune	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AC Immune has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AC Immune	$4.31M	62.57	-$85.03M	-$0.54	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

51.4% of AC Immune shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Solid Biosciences has a net margin of 0.00% compared to AC Immune's net margin of -245.32%. Solid Biosciences' return on equity of -71.35% beat AC Immune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AC Immune	-245.32%	-100.17%	-28.36%
Solid Biosciences	N/A	-71.35%	-60.58%

AC Immune has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market.

AC Immune presently has a consensus target price of $7.50, suggesting a potential upside of 183.02%. Solid Biosciences has a consensus target price of $18.18, suggesting a potential upside of 86.10%. Given AC Immune's higher possible upside, research analysts plainly believe AC Immune is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AC Immune	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

AC Immune beats Solid Biosciences on 8 of the 15 factors compared between the two stocks.

Get AC Immune News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACIU vs. The Competition

Export

Metric	AC Immune	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$269.70M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-4.91	11.62	273.16	25.45
Price / Sales	62.57	1,295.87	605.06	76.64
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	6.02	16.53	12.98	6.14
Net Income	-$85.03M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-8.62%	-0.31%	0.13%	-0.80%
1 Month Performance	11.81%	9.80%	7.08%	4.13%
1 Year Performance	29.90%	55.66%	24.67%	15.17%

AC Immune Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACIU AC Immune	2.4886 of 5 stars	$2.65 -2.2%	$7.50 +183.0%	+29.9%	$269.70M	$4.31M	N/A	140	Positive News
SVRA Savara	2.3875 of 5 stars	$5.62 +1.0%	$10.14 +80.6%	+60.4%	$1.15B	N/A	N/A	20	News Coverage Gap Up
JANX Janux Therapeutics	2.8717 of 5 stars	$18.81 +1.1%	$36.46 +93.8%	-20.6%	$1.15B	$24M	N/A	30	News Coverage
IMMX Immix Biopharma	2.9254 of 5 stars	$14.96 +9.9%	$21.29 +42.3%	+527.9%	$1.07B	N/A	N/A	9	High Trading Volume
AVTX Avalo Therapeutics	2.8477 of 5 stars	$19.61 +1.8%	$45.10 +130.0%	+110.9%	$1.05B	$59K	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACIU) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AC Immune (ACIU) Competitors

ACIU vs. SVRA, JANX, IMMX, AVTX, and SLDB

How does AC Immune compare to Savara?

Summary

How does AC Immune compare to Janux Therapeutics?

Summary

How does AC Immune compare to Immix Biopharma?

Summary

How does AC Immune compare to Avalo Therapeutics?

Summary

How does AC Immune compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AC Immune (ACIU) Competitors

ACIU vs. SVRA, JANX, IMMX, AVTX, and SLDB

How does AC Immune compare to Savara?

Which has stronger valuation and earnings, SVRA or ACIU?

Does the media prefer SVRA or ACIU?

Which has more volatility & risk, SVRA or ACIU?

Is SVRA or ACIU more profitable?

Do institutionals and insiders hold more shares of SVRA or ACIU?

Do analysts rate SVRA or ACIU?

Summary

How does AC Immune compare to Janux Therapeutics?

Do analysts rate ACIU or JANX?

Which has more volatility & risk, ACIU or JANX?

Which has preferable earnings & valuation, ACIU or JANX?

Does the media prefer ACIU or JANX?

Is ACIU or JANX more profitable?

Do institutionals and insiders have more ownership in ACIU or JANX?

Summary

How does AC Immune compare to Immix Biopharma?

Is ACIU or IMMX more profitable?

Which has stronger earnings & valuation, ACIU or IMMX?

Do institutionals & insiders hold more shares of ACIU or IMMX?

Do analysts recommend ACIU or IMMX?

Which has more volatility and risk, ACIU or IMMX?

Does the media prefer ACIU or IMMX?

Summary

How does AC Immune compare to Avalo Therapeutics?

Which has more risk & volatility, ACIU or AVTX?

Is ACIU or AVTX more profitable?

Do analysts recommend ACIU or AVTX?

Do institutionals and insiders believe in ACIU or AVTX?

Does the media prefer ACIU or AVTX?

Which has preferable valuation & earnings, ACIU or AVTX?

Summary

How does AC Immune compare to Solid Biosciences?

Does the media prefer ACIU or SLDB?

Which has stronger valuation & earnings, ACIU or SLDB?

Do insiders & institutionals hold more shares of ACIU or SLDB?

Is ACIU or SLDB more profitable?

Which has more risk and volatility, ACIU or SLDB?

Do analysts prefer ACIU or SLDB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACIU vs. The Competition

AC Immune Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools